The BRAVO Flow Diverter device diverts blood away from an aneurysm. Credit: Cerenovus.

Cerenovus, part of the Johnson & Johnson Medical Devices Companies, has received European CE mark approval for its BRAVO Flow Diverter device, which can be used to treat patients suffering from intracranial aneurysms.

The device is designed to divert blood flow from an aneurysm,  reducing the risk of rupture and a potential haemorrhagic stroke.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The BRAVO Flow Diverter is now among Cerenovus’s broad portfolio of devices used in endovascular treatment of haemorrhagic and ischaemic stroke. Its design aims to improve clinician ease of use and cost-effectively reduce the length of procedures.

Professor Patrick Brouwer, a senior consultant neurointerventionalist at Karolinska University Hospital in Sweden, evaluated the BRAVO Flow Diverter. He said: “Flow diverters are now widely used and, for many, have become the go-to option for the treatment of complex aneurysms. I believe the design of the BRAVO Flow Diverter, particularly the proximal and distal expansion rings, provides a fresh approach to treat aneurysms.”

Stroke affects 15 million people each year worldwide, according to the World Heart Federation, with haemorrhagic strokes accounting for 13% of all cases. The main cause of a haemorrhagic stroke is an aneurysm which occurs when a weakened region of a blood vessel expands until it ruptures and then bleeds into the brain.

Cerenovus worldwide president Daniella Cramp said: “The BRAVO Flow Diverter builds on our legacy of providing meaningful innovation to enable patients to live a life free from the burden of stroke. Our entry into the flow diverter market demonstrates our commitment to push the boundaries of stroke treatment and marks a key step towards changing the trajectory of stroke.”

Early evaluations will occur across Europe ahead of the European commercialisation of the device, which is currently not approved for use in the US.